Teva Pharmaceutical Industries Limited (TEVA) : Mondays money flow data in Teva Pharmaceutical Industries Limited (TEVA) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $34.41 million, whereas, $32.18 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.07, in favor of the bulls. The total money flow into the stock was $2.23 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $4.16 million. The total value of block trades done on upticks was $4.16 million. Teva Pharmaceutical Industries Limited (TEVA) fell $0.11 and traded at $54.1, down -0.2% for the day, over previous days close. On a weekly basis, the shares are 6.31% over the previous weeks close.
Teva Pharmaceutical Industries Limited has dropped 0.96% during the last 3-month period . Year-to-Date the stock performance stands at -16.53%. Shares of Teva Pharmaceutical Industries Limited rose by 6.22% in the last five trading days and 3.62% for the last 4 weeks.
Teva Pharmaceutical Industries Limited (NYSE:TEVA): On Mondays trading session , Opening price of the stock was $54.45 with an intraday high of $54.88. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $53.83. However, the stock managed to close at $54.1, a loss of 0.20% for the day. On the previous day, the stock had closed at $54.21. The total traded volume of the day was 4,805,469 shares.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.